# HD21 for Advanced Stages

> **NCT02661503** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Cologne** · enrollment: 1500 (actual)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** Bleomycin
- **DRUG:** Etoposide
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Procarbazine
- **DRUG:** Prednisone
- **DRUG:** Brentuximab Vedotin
- **DRUG:** Dacarbazine
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02661503
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-07
- **Primary completion:** 2022-12
- **Final completion:** 2025-09
- **Target enrollment:** 1500 (ACTUAL)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02661503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02661503, "HD21 for Advanced Stages". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02661503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*